Chordate Medical Holding AB (CMH) - Total Assets
Based on the latest financial reports, Chordate Medical Holding AB (CMH) holds total assets worth Skr18.04 Million SEK (≈ $1.94 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Chordate Medical Holding AB for net asset value and shareholders' equity analysis.
Chordate Medical Holding AB - Total Assets Trend (2015–2024)
This chart illustrates how Chordate Medical Holding AB's total assets have evolved over time, based on quarterly financial data.
Chordate Medical Holding AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Chordate Medical Holding AB's total assets of Skr18.04 Million consist of 43.8% current assets and 56.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 14.4% |
| Accounts Receivable | Skr1.30 Million | 7.4% |
| Inventory | Skr1.77 Million | 10.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr7.90 Million | 45.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Chordate Medical Holding AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Chordate Medical Holding AB.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chordate Medical Holding AB's current assets represent 43.8% of total assets in 2024, an increase from 21.9% in 2015.
- Cash Position: Cash and equivalents constituted 14.4% of total assets in 2024, down from 16.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 43.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 45.1% of total assets.
Chordate Medical Holding AB Competitors by Total Assets
Key competitors of Chordate Medical Holding AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Chordate Medical Holding AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.97 | 2.65 | 3.03 |
| Quick Ratio | 1.54 | 2.34 | 2.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr4.02 Million | Skr9.92 Million | Skr8.11 Million |
Chordate Medical Holding AB - Advanced Valuation Insights
This section examines the relationship between Chordate Medical Holding AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.15 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -20.2% |
| Total Assets | Skr17.53 Million |
| Market Capitalization | $29.05K USD |
Valuation Analysis
Below Book Valuation: The market values Chordate Medical Holding AB's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Chordate Medical Holding AB's assets decreased by 20.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Chordate Medical Holding AB (2015–2024)
The table below shows the annual total assets of Chordate Medical Holding AB from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr17.53 Million ≈ $1.89 Million |
-20.15% |
| 2023-12-31 | Skr21.96 Million ≈ $2.36 Million |
+17.78% |
| 2022-12-31 | Skr18.64 Million ≈ $2.01 Million |
-57.69% |
| 2021-12-31 | Skr44.06 Million ≈ $4.74 Million |
+41.15% |
| 2020-12-31 | Skr31.22 Million ≈ $3.36 Million |
+65.58% |
| 2019-12-31 | Skr18.85 Million ≈ $2.03 Million |
-10.74% |
| 2018-12-31 | Skr21.12 Million ≈ $2.27 Million |
-27.55% |
| 2017-12-31 | Skr29.15 Million ≈ $3.14 Million |
-29.11% |
| 2016-12-31 | Skr41.12 Million ≈ $4.43 Million |
-13.62% |
| 2015-12-31 | Skr47.61 Million ≈ $5.12 Million |
-- |
About Chordate Medical Holding AB
Chordate Medical Holding AB (publ), a medical technology company, engages in the development of products and solutions for neurostimulation treatment in Sweden. It offers Ozilia, a neuromodulation and medication-free treatment technology for chronic migraine and chronic rhinitis. The company was founded in 2005 and is based in Kista, Sweden.